About Us

About Us 2017-08-17T15:33:21+00:00

Leadership.

Steven E. Hall, PhDPresident & CEO
Steve brings more than 25 years of pharmaceutical experience to his role and is also a General Partner with Lilly Ventures. Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder. There he led a team in applying a novel discovery technology to a project that advanced from a novel screen to first patient dosed in just over three years, culminating in the acquisition of Serenex by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. Steve started his career as a medicinal chemist with the Squibb Institute for Medical Research and held positions of increasing responsibility for multiple projects in cardiovascular disease. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology. In addition to his role as CEO of Esanex, Steve also sits on the boards of Cavion, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Lysosomal Therapeutics, and Nimbus Therapeutics.
Everardus (Eric) Orlemans, Ph.DCSO and SVP, Development
Eric has over 30 years of experience in pharmaceutical research and development. Prior to joining Esanex, Eric was COO at Cognipharma, and before that he led development at both POZEN and Organon (clinical development for North and South America). Eric has extensive experience in both small and large organizations (up to 250 FTE; $400M projects budget). Eric has had overall responsibility for the successful submissions of about 20 NDA, MAA and GAYO dossiers and product approvals in US, EU, Japan and multiple dossiers in ROW and has had direct interactions with FDA, EMA and with MHW/KIKO (Japan). Eric’s expertise spans discovery through development, including clinical and regulatory strategies, program execution, clinical operations and CMC activities, as well as early discovery across multiple therapeutic areas including in analgesia, anesthesia, cardiovascular, CNS, gastrointestinal, oncology, and reproductive medicine. Eric is the author on more than 30 papers and 8 patents. Eric received his undergraduate degree in Chemistry at the University of Nijmegen, and his Ph.D. at the University of Twente, both in The Netherlands.
James M. Hinson, Jr, MD, FCCP CPIChief Medical Officer
Jim has nearly 30 years of clinical research experience, and for 17 years has been a founder and principle of Unicorn Pharma Consulting of Brentwood, LLC, a specialized firm specializing in providing medical, regulatory and operational consulting to small and midsize pharmaceutical and biotech companies. Jim, an internist and pulmonologist, has served roles in academic medicine as an investigator and research center administration and commercially sponsored research as a trial designer, product strategist and project leader. He has specific experience and expertise in research compliance, GCP training and certification, trial design, FDA strategy, analysis and regulatory presentations. He has participated in some capacity in over 300 trials, 16 successful NDAs or sNDAs (including labeling, safety or efficacy lead), and has had direct FDA interactions in most divisions of CDER, CBER and CDERH. He has served on approximately 25 data safety review committees and has chaired about 12 of them. He has advised over 40 clients, including midsize and large pharmaceutical companies.
Catherine Ross, BA Clinical Operations
Catherine has 27 years of clinical research experience, and for 10 years has been a principle of Unicorn Pharma Consulting of Brentwood, LLC, a specialized firm specializing in providing medical, regulatory and operational consulting to small and midsize pharmaceutical and biotech companies. Ms. Ross has served roles in Program management and drug development including (RFP) development, bid analysis, CRO selection, project planning, budgeting, staffing, resourcing, and vendor selection as well as being responsible for the overall conduct of the clinical trial from site startup through close-out. She has overseen drug development in numerous therapeutic areas, having managed over 30 trials, including 2 successful NDAs where she contributed to the Integrated Summary of Safety and the Integrated Summary of Efficacy. She has advised over 20 clients, including several midsize and large pharmaceutical companies.

Richard J Crawley, BSc. MSc.Regulatory Consultant
Richard has over 40 years of experience in the pharmaceutical industry in drug metabolism and pharmacokinetics, global regulatory affairs, as well as drug development planning and management. He has served in senior regulatory positions with The Wellcome Foundation (UK), Burroughs Wellcome (USA) and POZEN Inc. (USA) with extensive experience interacting with worldwide Regulatory Authorities, CTX, IND, CTA, MAA and NDA submission compilation and approval for ethical and OTC drug products. He has been involved in more than 25 successful MAA/NDA submissions for NCEs and 75 clinical trial applications globally and has extensive experience in dealing with global regulatory authorities. Richard has led global development programs for GlaxoWellcome, Solvay Pharmaceuticals, PPD Development and POZEN Inc. covering Phase 1 through Phase 4 development activities in multiple therapeutic areas.

Board of Directors.

Steven E. Hall, PhD
Steve is a General Partner at Lilly Ventures and brings more than 25 years of pharmaceutical experience to the role. Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder. There he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years, culminating in the acquisition of Serenex by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. Steve started his career as a medicinal chemist with the Squibb Institute for Medical Research and held positions of increasing responsibility for multiple projects in cardiovascular disease. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology. Steve currently sits on the boards of Cavion, Esanex, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Lysosomal Therapeutics, and Nimbus Therapeutics.

Richard Kent, M.D.
Rick is a Venture Partner with Intersouth Partners, one of the largest and most experienced venture capital funds in the southeast. Dr. Kent represents Intersouth as a board member of multiple biotechnology, pharmaceutical and medical device companies. Dr. Kent has more than 30 years of global pharmaceutical experience. Most recently he was CEO of Serenex, Inc., a venture backed biotechnology company acquired by Pfizer. Prior positions include CEO of Ardent Pharmaceuticals, Senior Vice President, Global Medical Affairs, and Chief Medical Officer for GlaxoSmithKline, and other senior positions within Glaxo Wellcome and Burroughs Wellcome. Dr. Kent has supervised dozens of INDs and over 20 successful NDAs (and equivalent submissions in Europe and the rest of the world) in a wide range of therapeutic areas including CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical Care, Cardiovascular, and Oncology. Dr. Kent received his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, San Diego. He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University’s medical faculty. He is board certified in both internal medicine and cardiology.
Richard J. Miller, M.S.
Rick has over 24 years of private equity investment and consulting experience and is the founder and Managing Member of Shippan Point Advisors LLC (“SPA”), a financial and operating advisory firm. SPA’s clients include investment buyout, late stage and venture investors as well as large public and private operating companies. Rick served as an investment partner and as an executive consultant/ chairman/CEO to several portfolio companies. Prior to founding Shippan Point Advisors, Rick was an executive at Onsite Access, Inc., a telecommunications company. Prior to Onsite, Rick was a Senior Vice President and co-head of the Healthcare Group at GE Equity, a division of GE Capital, where he led successful strategic private equity investments in healthcare and technology-driven business service companies. Before joining GE, Rick was a Partner at RFE Investment Partners, a private equity firm focused on late stage investments in a variety of industries. Rick is a Certified Public Accountant and was employed by Arthur Young & Co (now Ernst & Young) where he was selected for a position as a Senior Tax Manager in the National Tax Office in Washington D.C. Rick holds a Master’s Degree in Taxation from Pace University and graduated from Le Moyne College with a Bachelor of Science degree in Accounting.

Investors.

BioCrossroads

BioCrossroads serves as a catalyst for the continued growth of Indiana’s robust life sciences industry.  As part of its mission, BioCrossroads has established life sciences focused, return-driven investment funds. BioCrossroads has also been strongly supported by Indiana’s corporate and academic life sciences leadership, and has partnered with these stakeholders in several ways, including investment and enterprise-formation activities.  Managed by BioCrossroads, the Funds make investments in early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech and health information technology products and platforms and will continue to focus on forming promising companies around innovative ideas. In addition to Esanex, portfolio companies include Algaeon, Assembly Biosciences (Nasdaq:ASMB), Apexian Therapeutics, MB2 (purchased by Novo Nordisk, 2015), Diagnotes, Speechvive, Allinaire Therapeutics and Calibrium (purchased by Novo Nordisk, 2015).

Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company. Our investment philosophy drives us to seek great companies with compelling life science innovations. We partner actively with the management teams of our portfolio companies to realize the potential of their technologies. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. We are currently targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline in the United States and Europe.

Intersouth Partners is one of the most active and experienced venture capital firms in the Southeast, having invested in more than 100 private companies. Founded in 1985, Intersouth manages $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast.  Based in Durham, North Carolina, Intersouth Partners seeks a broad range of investment opportunities in the technology and life science sectors. Our experienced team has full-cycle experience in the complex matters associated with investing in fledgling companies, including technology assessment and transfer, management team development, corporate partnering, sales growth and successful exits.

Ritchie Capital Management, L.L.C. is a privately-owned hedge fund sponsor. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity and alternative investment markets across the globe. The firm’s alternative investments include investment in private equity markets, venture capital, real estate markets, and energy and insurance products. It employs multiple-strategies including capital structure arbitrage, convertible bond arbitrage, risk arbitrage, distressed, global macro, fixed income arbitrage, volatility arbitrage, and equity long/short, as well as energy, weather, and insurance-linked strategies to make its investments. The firm employs fundamental analysis while making its investments. It conducts external research to create its portfolios. Ritchie Capital Management, L.L.C. was founded in 1997 and is based in Grand Cayman, Cayman Islands.